Evidence map›Paper›PMID 42554961›Full record

ArticlePain and therapy2026

Efficacy of Neuromodulation Therapy for Neuropathy Symptom Reduction and Functional Improvement.

Stephen M Erle, Madelyn J Reilly, Andrew Lang, Alaa Abd-Elsayed

Abstract read
In one paragraph

Article in Pain and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Stephen M ErleNational Neuropathy Center, Mechanicsville, VA, USA.
Madelyn J ReillyDepartment of Anesthesiology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.ORCID http://orcid.org/0009-0005-8828-7740
Andrew LangNational Neuropathy Center, Mechanicsville, VA, USA.
Alaa Abd-ElsayedDepartment of Anesthesiology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA. alaaawny@hotmail.com.ORCID http://orcid.org/0000-0002-9890-7860

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTargeted neuromodulation therapies are increasingly used for the management of peripheral neuropathy; however, data on symptom and functional outcomes following standardized treatment courses remain limited. This report evaluates the efficacy of NeuroGen Neuromodulation treatments administered at the National Neuropathy Center, focusing on changes in sensory symptoms and functional task performance from the first treatment (T1) to the twelfth treatment (T12) over a mean treatment duration of 36 sessions.

methodsPatients completing a standardized 12-treatment course using the NeuroGen Neuromodulation device were analyzed. Outcomes included patient-reported sensory symptoms (tingling, numbness, and pain) and measures of functional task performance. Changes from baseline (T1) to posttreatment (T12) were assessed to determine treatment effectiveness, response patterns, and areas for clinical optimization.

resultsPatients demonstrated clear and measurable benefits following completion of 12 treatments. The greatest improvements were observed in sensory symptoms, with tingling, numbness, and pain each improving by approximately one point on the severity scale. More than half of patients achieved clinically meaningful relief in these sensory domains. Functional improvement was more modest, with meaningful gains observed in approximately one-quarter to one-third of patients. Nonresponse rates were low, although residual symptoms and functional limitations remained common.

conclusionsThe standard NeuroGen Neuromodulation treatment protocol provides substantial relief of sensory neuropathic symptoms, with consistent benefits across patients. While functional gains were less pronounced, the low nonresponse rate supports overall treatment effectiveness. Persistent symptoms in some patients suggest a potential role for maintenance therapy and adjunctive interventions to optimize long-term outcomes.

Indexed as

National neuropathy centerNeuroGen neuromodulation deviceNeuromodulationNeuropathic painPeripheral nerve stimulationPeripheral neuropathy

Identifiers

PMID42554961
PMCPMC13624247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.